Trial Profile
Assessment of tumoral heterogeneity in NSCLC treated with bevacizumab: A prospective study.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 01 Sep 2015
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Antineoplastics
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 01 Sep 2015 New trial record